Skip to main content
. Author manuscript; available in PMC: 2023 Aug 30.
Published in final edited form as: ACS Infect Dis. 2022 Apr 11;8(5):1022–1030. doi: 10.1021/acsinfecdis.1c00629

Figure 4.

Figure 4.

Antiviral activity of SARS-CoV-2 PLpro inhibitors GRL0617 (A), EACC(B), KY-226 (C), and tropifexor (D) against SARS-CoV-2 in Calu-3 cells. The results were quantified by immunofluorescence assay. Values represent the average ± standard deviation of three replicates.